IMCD stops its business in Russia
ROTTERDAM, The Netherlands (29 April 2022) – The Management Board of IMCD N.V. (hereafter “IMCD” or the “Company”) has decided to discontinue business in Russia and close its offices in St. Petersburg and Moscow. This follows IMCD’s decision of early March to suspend import and export operations in Russia and scale down the local business due to increasing international sanctions.
IMCD will wind down its operations and continue to support the employees in its Russian offices throughout the transition process. Upon completion, IMCD will no longer have a presence in Russia.
The discontinuation of activities in Russia has no material impact on IMCD’s results for 2022.
This press release contains information that may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation and was issued on 29 April 2022, 07:00 a.m. CET.
About IMCD N.V.
IMCD, based in Rotterdam, the Netherlands, is a market leader in the marketing, sales, and distribution of speciality chemicals and ingredients. Its result-driven professionals provide market-focused solutions to suppliers and customers across EMEA, Americas and Asia-Pacific, offering a range of comprehensive product portfolios, including innovative formulations that embrace industry trends.
Listed at Euronext, Amsterdam (IMCD), IMCD realised revenues of EUR 3,435 million in 2021 with more than 3,700 employees in over 50 countries on six continents. IMCD's dedicated team of technical and commercial experts work in close partnership to tailor best-in-class solutions and provide value through expertise for around 56,000 customers and a diverse range of world-class suppliers.
For further information, please visit www.imcdgroup.com.
Media contact IR contact
IMCD Group IMCD NV
Marnie Kontovraki Cecile Westerhuis
Group Communications Director Company Secretary
+31 10 290 86 84 +31 10 290 86 84
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed28.5.2022 12:01:09 CEST | Press release
FRO – Private acquisitions of Euronav shares in exchange for Frontline shares completed Frontline Ltd. (“Frontline” or the "Company") (NYSE: FRO – OSE: FRO) announces that it has agreed to acquire a total of 5,955,705 shares in Euronav N.V. (NYSE: EURN & Euronext: EURN) (“Euronav”) representing 2.95% of the outstanding shares in privately negotiated share exchange transactions with certain shareholders of Euronav N.V. where such shareholders of Euronav N.V. receive consideration shares in Frontline. Frontline will issue a total of 8,337,986 new shares as a result of these transactions, equivalent to an exchange ratio of 1.4. Frontline will be entitled to the declared USD 0,06 dividend to be paid by Euronav on the acquired shares on 8 June 2022. Settlement is expected to take place on or about 1 June 2022 by delivery of existing shares through a share lending arrangement with Frontline's main shareholder Hemen Holding Ltd. Following completion of the issue of the new Frontline shares, F
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma28.5.2022 00:58:29 CEST | Press release
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1 Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indicati
ObsEva Announces Corporate Updates27.5.2022 22:01:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland– May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc. (JGB), which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of ObsEva not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Am
CONDITIONS FOR PURCHASES OF CORPORATE BONDS27.5.2022 16:20:00 CEST | Press release
Bid procedure, 2022-06-01BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: HEMSO FASTIGHETS AB: XS2173253407, 2025-05-13 HEMSO FASTIGHETS AB: XS2269194572, 2023-12-07 VASAKRONAN AB: SE0010599183, 2023-12-20 VASAKRONAN AB: XS2391917205, 2025-03-28 ESSITY AB: XS2355204608, 2025-01-17 SCANIA CV AB: XS2297918349, 2023-11-11 SCANIA CV AB: XS2382157571, 2024-09-02 ELECTROLUX AB: XS2152294679, 2023-04-06 ELECTROLUX AB: XS1969611943, 2024-03-27 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2022-04-27Bid date2022-06-01Bid times10.30-11.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS2173253407: 30 mln SEK +/-30 mln SEK XS2269194572: 30 mln SEK +/-30 mln SEK SE0010599183: 30 mln SEK +/-30 mln SEK XS2391917205: 30 mln SEK +/-
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS27.5.2022 16:20:00 CEST | Press release
Bid procedure, 2022-06-03BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01 Bid date2022-06-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3113: 250 mln SEK +/-125 mln SEK 3114: 250 mln SEK +/-125 mln SEK Highest permitted bid volume (corresponding nominal amount)3113: 250 mln SEK per bid 3114: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-06-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-05-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be